I picked 'A' for this week aka Agilent Technologies due to

New Post Public Reply Private Reply Replies (1) Message Board
joey68
393
I picked 'A' for this week aka Agilent Technologies due to a dream i had last night. weird.
View My Board Here:
http://investorshangout.com/Joeys-Investment-Board-91611/


Invite Only

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.

Disclaimer:
As used herein, the terms "You" and "Your" shall mean you, individually, the reader, and each other party on whose behalf you may use the contained information at any time.
All references to "My", "I", and “The writer of the above post” shall refer to the creator of the username Joey68.

Do NOT invest unless you are prepared to sustain a total loss of the money you have invested plus any commission or other transaction charges.

There is a very high degree of risk involved in trading and investing. Past results are not indicative of future returns. I assume no responsibility for your trading and investment results. You should NOT rely on the information in the above post to make any decision or take any action.

ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are OPINION and NOT fact and are for entertainment purposes only. Do your own research and make your own decisions based on your own conclusions.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are NOT advice, and are NOT designed to substitute the expertise and judgment of a professional. It is your responsibility to seek investment advice during all stages of your investments. It is your responsibility to evaluate the accuracy, completeness and usefulness of the information in the above post.
I am NOT a professional.
I do NOT work for you.
My posts are NOT investment advice. I am not paid to post.
There is no correlation between the number of posts I write per day and your assumed success of a company.
It is NOT my responsibility to inform you of my own personal investment decisions.
It is NOT my responsibility to inform you when it is time for you to buy, hold, and/or sell a position.
I have no control over, and am not responsible for the actions of others who copy, store, edit, change, prepare any derivative work of or alter in any way any of the content provided in my posts.
Errors and Omissions expected. The writer of the above post accepts no liability or responsibility for any errors or omissions contained in the above post or contained within this Disclaimer.
The writer of the above post shall NOT accept any liability for the accuracy or completeness of the information contained in the above post, for any reliance placed by any person on the information contained in the above post, or for any damage or loss, however caused, in connection with the use or reliance on any information contained in the above post.
The above post may contain links to websites owned and operated by third parties. These links are provided for informational purposes only and are NOT endorsed by the writer of the above post. The writer of the above post has no control over the contents of any linked website and bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.
YOU ACCESS ALL LINKS ENTIRELY AT YOUR OWN RISK.
The writer of the above post makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by, or the information contained on these websites.
The writer of the above post accepts no liability for any damage or loss, however caused, in connection with the use of or reliance on any information, material, products, or services contained on or accessed through any such linked websites.

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 371

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 177

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Updated Category News Views 328

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 254

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
Breakthrough T1D Pushes Global T1D Awareness Forward

Updated Category News Views 214

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 250

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 353

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 28

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 298

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 409

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading

Top 5 Most Recently Viewed Articles

Novartis Fabhalta® Breakthrough in PNH Treatment Showcased

Updated Category News Views 290

Novartis Fabhalta® Achieves Significant Hemoglobin Improvements In recent studies, Novartis has showcased promising results from its Phase IIIB APPULSE-PNH study regarding Fabhalta (iptacopan), designed for adult patients suffering from paroxysmal nocturnal hemoglobinuria (PNH). Patients who switched from anti-C5 therapies demonstrated noteworthy improvement in their...

Continue Reading
Insights into Indonesia's Economic Landscape for Credit Investors

Updated Category News Views 208

Understanding Indonesia's Market Dynamics This week, Gimme Credit unveiled a new Indonesia Country Report that delves into the recent fluctuations in the equity market and its potential ripple effects on foreign exchange and bond markets. The inquiry raises fundamental questions about whether these shifts could necessitate a higher risk premium for those investing in...

Continue Reading
Pliant Therapeutics to Showcase Innovations at Key Healthcare Conference

Updated Category News Views 187

Introduction to Pliant Therapeutics' Participation Pliant Therapeutics, Inc. (NASDAQ: PLRX), a dedicated force in the clinical-stage biotechnology sector, is set to make waves at an upcoming healthcare conference. The event serves as a platform for the company to showcase its integrin-based therapeutics—game-changing innovations aimed at treating various serious health...

Continue Reading
OSB Group PLC Financial Performance Overview for 2025

Updated Category News Views 322

OSB Group PLC Trading Update Summary OSB GROUP PLC, a specialist lending and retail savings group, is pleased to share its trading update for the nine-month period concluding on 30 September 2025. This report highlights the Group's steady growth and enhanced financial performance in line with expectations and strategic objectives. Performance Insights for the Nine-Month...

Continue Reading
Toll Brothers Unveils Luxurious Homes at Ridge Pointe Estates

Updated Category News Views 222

Toll Brothers Unveils New Luxury Homes at Ridge Pointe Estates Toll Brothers, Inc. (NYSE: TOL), recognized as a leader in the luxury home construction industry, has introduced its latest community, Ridge Pointe Estates. This community, now officially open, offers prospective homeowners a blend of elegance and modern living. Located within a serene setting, Ridge Pointe...

Continue Reading